| Autor: |
Büttner D, Kramer JS, Klingler FM, Wittmann SK, Hartmann MR, Kurz CG, Kohnhäuser D, Weizel L, Brüggerhoff A, Frank D; Institute of Medical Microbiology and Infection Control , Goethe University Hospital , Paul-Ehrlich-Straße 40 , 60596 Frankfurt , Germany., Steinhilber D, Wichelhaus TA; Institute of Medical Microbiology and Infection Control , Goethe University Hospital , Paul-Ehrlich-Straße 40 , 60596 Frankfurt , Germany., Pogoryelov D, Proschak E |
| Jazyk: |
angličtina |
| Zdroj: |
ACS infectious diseases [ACS Infect Dis] 2018 Mar 09; Vol. 4 (3), pp. 360-372. Date of Electronic Publication: 2017 Dec 12. |
| DOI: |
10.1021/acsinfecdis.7b00129 |
| Abstrakt: |
Pathogens, expressing metallo-β-lactamases (MBLs), become resistant against most β-lactam antibiotics. Besides the dragging search for new antibiotics, development of MBL inhibitors would be an alternative weapon against resistant bacterial pathogens. Inhibition of resistance enzymes could restore the antibacterial activity of β-lactams. Various approaches to MBL inhibitors are described; among others, the promising motif of a zinc coordinating thiol moiety is very popular. Nevertheless, since the first report of a thiol-based MBL inhibitor (thiomandelic acid) in 2001, no steps in development of thiol based MBL inhibitors were reported that go beyond clinical isolate testing. In this study, we report on the synthesis and biochemical characterization of thiol-based MBL inhibitors and highlight the challenges behind the development of thiol-based compounds, which exhibit good in vitro activity toward a broad spectrum of MBLs, selectivity against human off-targets, and reasonable activity against clinical isolates. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
